CFAP52 as A Potential Drug Target Or Biomarker for HCC (G146845)

Target Name: CFAP52

NCBI ID: G146845

CFAP52

CFAP52 as A Potential Drug Target Or Biomarker for HCC

CFAP52 (WD40-repeat protein upregulated in HCC) is a protein that has been identified as a potential drug target or biomarker in the context of hepatocellular carcinoma (HCC), a type of liver cancer that is the most common cause of cancer-related deaths worldwide. The discovery of CFAP52 was made using a computational screening approach, in which a database of gene expression was used to identify genes that were highly expressed in HCC samples.

The gene encoding CFAP52 has an interesting expression profile, with high levels of expression in the liver and other tissues, including the brain, heart, and pancreas. It is also overexpressed in HCC samples, which suggests that it may be a promising biomarker for this disease.

In addition to its expression profile, CFAP52 has several potential drug targets. For example, it can interact with the protein PDGFB, which is a key regulator of cell proliferation and has been implicated in the development of HCC. By modulating PDGFB activity, CFAP52 may be able to inhibit the growth and spread of HCC tumors.

Another potential drug target for CFAP52 is the protein NF-kappa-B, which is a transcription factor that regulates inflammation and immune responses. HCC tumors often have increased NF-kappa-B activity, which may contribute to their malignant properties. By targeting CFAP52, drugs that inhibit NF-kappa-B activity may be able to treat HCC.

CFAP52 has also been shown to be involved in the regulation of cell adhesion. In HCC, the loss of cell adhesion is a common feature, which can contribute to tumor progression and the development of invasive and metastatic forms. By re-establishing cell adhesion, CFAP52 may be able to inhibit the growth and spread of HCC tumors.

In addition to its potential drug targets, CFAP52 is also a promising biomarker for HCC. The high levels of its expression in HCC samples make it a potential candidate for diagnostic assays, such as liquid chromatography-based assays or gene expression arrays. Additionally, its expression may be sensitive to changes in cellular environment, such as the presence of drugs or other signaling molecules. This could make CFAP52 an attractive target for researchers looking for new diagnostic or therapeutic approaches.

In conclusion, CFAP52 is a promising protein for the development of new drugs or biomarkers in the context of HCC. Its high expression levels and potential drug targets make it an attractive target for researchers looking to improve treatment outcomes for this disease. Further studies are needed to fully understand the role of CFAP52 in HCC and to develop effective therapies based on its properties.

Protein Name: Cilia And Flagella Associated Protein 52

Functions: Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (By similarity). Important for proper ciliary and flagellar beating. May act in cooperation with CFAP45 and axonemal dynein subunit DNAH11 (PubMed:33139725). May play a role in cell growth and/or survival (PubMed:15967112)

The "CFAP52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets